These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11563941)

  • 21. Attitudes, knowledge, risk perceptions and decision-making among women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2 and their spouses.
    Bluman LG; Rimer BK; Regan Sterba K; Lancaster J; Clark S; Borstelmann N; Iglehart JD; Winer EP
    Psychooncology; 2003; 12(5):410-27. PubMed ID: 12833555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of proband mediated information dissemination in families with a BRCA1/2 gene mutation.
    Sermijn E; Goelen G; Teugels E; Kaufman L; Bonduelle M; Neyns B; Poppe B; De Paepe A; De Grève J
    J Med Genet; 2004 Mar; 41(3):e23. PubMed ID: 14985394
    [No Abstract]   [Full Text] [Related]  

  • 23. Factors associated with decisions about clinical BRCA1/2 testing.
    Armstrong K; Calzone K; Stopfer J; Fitzgerald G; Coyne J; Weber B
    Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1251-4. PubMed ID: 11097234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The counselees' self-reported request for psychological help in genetic counseling for hereditary breast/ovarian cancer: not only psychopathology matters.
    Vos J; van Asperen CJ; Oosterwijk JC; Menko FH; Collee MJ; Gomez Garcia E; Tibben A
    Psychooncology; 2013 Apr; 22(4):902-10. PubMed ID: 22740372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The battle over BRCA1 goes to court; BRCA2 may be next.
    Marshall E
    Science; 1997 Dec; 278(5345):1874. PubMed ID: 9417630
    [No Abstract]   [Full Text] [Related]  

  • 26. Genetic counselling and testing for hereditary breast and ovarian cancer: the gent(le) approach.
    De Vos M; Poppe B; Delvaux I; Mortier G; Claes K; Messiaen L; De Paepe A
    Dis Markers; 1999 Oct; 15(1-3):191-5. PubMed ID: 10595277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Marker segregation information in breast/ovarian cancer genetic counseling: is it still useful? Groupe Génétique et Cancer de la Fédération Nationale des Centres de Lutte Contre le Cancer.
    Essioux L; Girodet C; Sinilnikova O; Pagès S; Eisinger F; de Résende S; Maugard C; Lanoë D; Longy M; Bignon YJ; Sobol H; Bonaïti-Pellié C; Stoppa-Lyonnet D
    Am J Med Genet; 1998 Sep; 79(3):175-83. PubMed ID: 9788557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psychological impact of receiving a BRCA1/BRCA2 test result.
    Lodder L; Frets PG; Trijsburg RW; Meijers-Heijboer EJ; Klijn JG; Duivenvoorden HJ; Tibben A; Wagner A; van der Meer CA; van den Ouweland AM; Niermeijer MF
    Am J Med Genet; 2001 Jan; 98(1):15-24. PubMed ID: 11426450
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Experience at Sheba Hospital in oncogenetic counseling and genetic testing of women with a high risk for breast and ovarian cancer].
    Theodor L; Shiri-Sverdlov R; Yechezkel GH; Bar-Sade RB; Gak E; Friedman I; Kruglikova A; Ben-Baruch G; Risel S; Papa MZ; Goldman B; Friedman E
    Harefuah; 1998 Apr; 134(8):593-9, 672. PubMed ID: 10911419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes. EC Demonstration Project on Familial Breast Cancer.
    Chang-Claude J; Becher H; Caligo M; Eccles D; Evans G; Haites N; Hodgson S; Møller P; Weber BH; Stoppa-Lyonnet D
    Dis Markers; 1999 Oct; 15(1-3):53-65. PubMed ID: 10595253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Communicating genetic risk: pros, cons, and counsel.
    Penson RT; Seiden MV; Shannon KM; Lubratovich ML; Roche M; Chabner BA; Lynch TJ
    Oncologist; 2000; 5(2):152-61. PubMed ID: 10794806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Familial breast-ovarian cancer syndromes: BRCA1 and BRCA2.
    Berchuck A; Carney M; Lancaster JM; Marks J; Futreal AP
    Clin Obstet Gynecol; 1998 Mar; 41(1):157-66. PubMed ID: 9504233
    [No Abstract]   [Full Text] [Related]  

  • 33. The decision to test in women receiving genetic counseling for BRCA1 and BRCA2 mutations.
    Kelly K; Leventhal H; Andrykowski M; Toppmeyer D; Much J; Dermody J; Marvin M; Baran J; Schwalb M
    J Genet Couns; 2004 Jun; 13(3):237-57. PubMed ID: 15604634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium.
    Burke W; Daly M; Garber J; Botkin J; Kahn MJ; Lynch P; McTiernan A; Offit K; Perlman J; Petersen G; Thomson E; Varricchio C
    JAMA; 1997 Mar; 277(12):997-1003. PubMed ID: 9091675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences between women who pursued genetic testing for hereditary breast and ovarian cancer and their at-risk relatives who did not.
    Katapodi MC; Northouse L; Pierce P; Milliron KJ; Liu G; Merajver SD
    Oncol Nurs Forum; 2011 Sep; 38(5):572-81. PubMed ID: 21875844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic testing for breast cancer predisposition.
    Gauthier-Villars M; Gad S; Caux V; Pagès S; Blandy C; Stoppa-Lyonnet D
    Surg Clin North Am; 1999 Oct; 79(5):1171-87, xxi. PubMed ID: 10572557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A whisper-game perspective on the family communication of DNA-test results: a retrospective study on the communication process of BRCA1/2-test results between proband and relatives.
    Vos J; Menko F; Jansen AM; van Asperen CJ; Stiggelbout AM; Tibben A
    Fam Cancer; 2011 Mar; 10(1):87-96. PubMed ID: 20852944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ethical aspects of genetic counseling in familial breast and ovarian cancer. Combining applied theory and reflective practice.
    Goelen G; Rigo A; Neyns B; Betz W; De Grève J
    Ann N Y Acad Sci; 1997 Dec; 833():170-2. PubMed ID: 9616750
    [No Abstract]   [Full Text] [Related]  

  • 39. Disclosure of genetics research results after the death of the patient participant: a qualitative study of the impact on relatives.
    Ormondroyd E; Moynihan C; Watson M; Foster C; Davolls S; Ardern-Jones A; Eeles R
    J Genet Couns; 2007 Aug; 16(4):527-38. PubMed ID: 17492498
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Communication with close and distant relatives in the context of genetic testing for hereditary breast and ovarian cancer in cancer patients.
    Claes E; Evers-Kiebooms G; Boogaerts A; Decruyenaere M; Denayer L; Legius E
    Am J Med Genet A; 2003 Jan; 116A(1):11-9. PubMed ID: 12476445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.